Coronaviruses and SARS-CoV-2: A Brief Overview : Anesthesia & Analgesia

Secondary Logo

Journal Logo

COVID-19 Articles

Coronaviruses and SARS-CoV-2: A Brief Overview

Ludwig, Stephan PhD*; Zarbock, Alexander MD

Author Information
Anesthesia & Analgesia 131(1):p 93-96, July 2020. | DOI: 10.1213/ANE.0000000000004845
  • Free


In late December 2019, several cases of pneumonia of unknown origin were reported from China, which in early January 2020 were announced to be caused by a novel coronavirus. The virus was later denominated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined as the causal agent of coronavirus disease 2019 (COVID-19). Despite massive attempts to contain the disease in China, the virus has spread globally, and COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. Here we provide a short background on coronaviruses, and describe in more detail the novel SARS-CoV-2 and attempts to identify effective therapies against COVID-19.

In late December 2019, several cases of pneumonia of unknown origin were reported from China, which in early January 2020 were announced to be caused by a novel coronavirus. The virus was later denominated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined as the causal agent of coronavirus disease 2019 (COVID-19). Despite intensive, wide-scale attempts to contain the disease in China, the virus has spread around the world in record time, and COVID-19 was thus declared to be a pandemic by the World Health Organization (WHO) in March 2020. Here we provide a short background on coronaviruses and their origin, and we describe in more detail the novel SARS-CoV-2 and the efforts thus far to identify effective therapies against COVID-19.


Because they provide care for COVID-19 patients and frequently perform procedures that generate aerosol (eg, endotracheal intubation, open suctioning, nebulized treatments), anesthesiologists and intensivists are especially at risk to be exposed to the novel coronavirus, putting them at a very high risk for infection. This is demonstrated by a recent publication showing that health care workers have a higher infection rate compared to the normal population.1 In addition, given that anesthesiologists and intensivists care for these patients, they should have basic knowledge of SARS-CoV-2 and the course of COVID-19 to effectively treat these patients and to optimally protect themselves.


CoV are found globally in humans and many different animal species. They are classified in the Orthocoronaviridae subfamily (order: Nidovirales, subordination: Cornidovirineae, family: Coronaviridae).2 CoV can be grouped into 4 genera, including α-/β-/γ-/δ-CoV and α- and β-CoV can infect mammals, while γ- and δ-CoV primarily infect birds.

CoV are enveloped viruses with a lipid membrane derived from the host cell, in which viral surface proteins are embedded. The proteins protruding from the viral membrane (especially the spike [S] protein) give these pathogens their characteristic halo-like appearance under the electron microscope, which has led to the name corona (Latin: garland, crown).3

All CoV have in common that their genome is in the form of a single-stranded ribonucleic acid (RNA) with positive polarity, meaning that the base sequence of the RNA is in the 5′→3′ orientation and corresponds to the later messenger RNA (mRNA). With a length of 26.4–31.7 kilobases, the genome of CoV is the largest RNA genome of all known RNA viruses.4

Besides a number of nonstructural proteins including the RNA-dependent RNA polymerase (RdRp), the viral RNA encodes 4 essential structural proteins, namely the nucleocapsid (N) protein surrounding the RNA genome and 3 membrane proteins: the S-glycoprotein, the matrix (M) protein, and the envelope (E) protein.5 The S-glycoprotein on the surface of CoV can attach to the cellular receptor, angiotensin-converting enzyme 2 (ACE2) on the surface of human cells.6 ACE2 is found in the lower respiratory tract of humans and regulates both the cross-species and human-to-human transmission.7

CoV have a high mutation rate due to their error-prone RdRp, which is responsible for the duplication of genetic information.8 In addition, homologous recombinations often occur in CoV.9 These properties have contributed to a great diversity of CoV in nature, which enables these viruses to infect numerous species.

The first coronavirus described was isolated from chicken embryos in 1937, the Infectious Bronchitis Virus (IBV).10 Since then, numerous CoV have been detected in a wide variety of animals, including wild animals, farm animals, and pets. They are divided into the genera of the mammalian-associated α- and β-CoV and the bird-associated γ- and δ-CoV.

Various CoV are important in veterinary medicine such as transmissible gastroenteritis coronavirus (TGEV) or porcine epidemic diarrhea virus (PEDV) that can cause severe diarrhea in pigs. The spectrum of coronavirus diseases in animals ranges from mild to severe intestinal, respiratory, or systemic diseases.11 However, there are also many coronavirus infections in animals that do not appear to cause any symptoms. The presence of CoV in a wide variety of animal species strongly suggested that these pathogens are of zoonotic origin and are transmitted from wild animals to humans.

In particular, the SARS pandemic, in 2002–2003, has led to an increasing number of studies in wild animals on all continents. The greatest diversity of CoV has so far been detected in bats.12 This has led to the hypothesis that at least the more recent CoV introductions to humans were originally bat viruses that spread to an intermediate animal (eg, the Himalayan palm civet for SARS-CoV and the dromedary camel for the Middle East respiratory syndrome [MERS]-CoV), which then exposed humans to the viruses. However, it can be assumed that there are still some gaps in the detection of zoonotic CoV in wild animal populations. In particular, the data situation for economically and/or politically unstable regions of the world is still incomplete.12


The first human coronaviruses (HCoV) were described in the 1960s and were designated HCoV-229E and HCoV-OC43.13,14 There are now 4 endemic HCoV known (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1) that circulate worldwide in the human population. In most cases, these endemic HCoV cause relatively mild diseases of the upper and lower respiratory tract and are estimated to account for about a third of all “common colds” in humans. Asymptomatic infections have also been described. In some cases, especially in immunosuppressed individuals, children, or persons with existing pulmonary diseases, progression to acute respiratory failure can also occur.15

The situation completely changed with the appearance of the SARS-CoV.16 This virus caused serious human respiratory diseases in China in 2002–2003. Approximately 8000 people were affected by the disease at that time, with case fatality rate (mortality rate) of around 9.5%. SARS-CoV spread could be stopped by the rapid development of a detection method and extensive measures to isolate infected individuals. Subsequent studies in wild animals showed that SARS-related CoV are found in bats and civet cats, hence it was assumed that the virus spread from the civet cat to humans, followed by human-to-human spread.17

While no human infections with the original SARS virus have been reported since 2004, another CoV dangerous for humans emerged in 2012. The MERS-CoV was isolated for the first time from a patient who was hospitalized with acute pneumonia in Saudi Arabia.18 By 2019, around 2500 MERS-CoV infections have been reported in humans, with about a 30% case fatality rate.14 The main risk area for MERS-CoV infections is the Arabian Peninsula. Infections were reported to be both through human-to-human transmission and through contact with dromedaries (camels). These animals appear to represent a reservoir for MERS-CoV.19


At the end of December 2019, China reported the increasing occurrence of pneumonia in the city of Wuhan, Hubei province. In January 2020, a novel β-CoV was identified as the cause.20 When the virus was first isolated from pneumonia cases in Wuhan, China, in December 2019, it was named 2019 novel coronavirus (2019-nCoV). As more information and genetic analyses became available, the virus was given the official name of SARS-CoV-2 by the International Committee for Taxonomy of Viruses, while the WHO named the disease caused by the virus, COVID-19.

The genome of the new coronavirus shows similarities to other β-CoV found in bats.20 SARS-CoV-2 is 96.2% identical to a bat CoV RaTG13, whereas it shares 79.5% identity to SARS-CoV. It can therefore be assumed that the virus originally came from bats and has been transmitted over time to other animal hosts and ultimately to humans.

Although the degree of diversification of SARS-CoV-2 is lower than that of, for example, influenza viruses, the divergence of 2 prevalent evolvement types of SARS-CoV-2, L type (≈ 70%) and S type (≈ 30%), was reported.21 According to this study, strains in L type, derived from S type, are evolutionarily more aggressive and contagious. It is clear now that SARS-CoV-2 also uses ACE2 as a cellular receptor to infect humans.22

SARS-CoV-2 is efficiently transmitted from person-to-person and has thus able to spread rapidly across all continents in our globalized world. In the resulting COVID-19 pandemic, 601,478 people have been infected and 27,961 patients have died so far (as of March 28, 2020, source: Johns Hopkins University).


As an emerging acute respiratory infectious disease, COVID-19 primarily spreads through the respiratory tract, by droplets, respiratory secretions, and direct contact.23 In addition, it has been reported that SARS-CoV-2 was isolated from fecal swabs and blood,24 indicating the possibility of multiple routes of transmission. However, this needs further clarification.

The current data suggest an incubation period of 1–14 days, in most cases 3–7 days. The virus is highly transmissible in humans and causes severe problems especially in the elderly and people with underlying chronic diseases. COVID-19 patients typically present with specific, similar symptoms, such as fever, malaise, and cough.25,26 Most adults or children infected with SARS-CoV-2 have presented with mild flu-like symptoms, but a few patients are in critical condition and rapidly develop acute respiratory distress syndrome (ARDS), respiratory failure, multiple organ failure, and even death.27

According to a recent report, the common clinical manifestations of COVID-19 included fever (88.7%), cough (67.8%), fatigue (38.1%), sputum production (33.4%), shortness of breath (18.6%), sore throat (13.9%), and headache (13.6%).28 A minor number of patients manifested gastrointestinal symptoms, with diarrhea (3.8%) and vomiting (5.0%). Fever and cough were the dominant symptoms, whereas upper respiratory symptoms and gastrointestinal symptoms were rare. The case fatality rate increases with the severity of illness and can reach up to 49% in critically ill patients.1 Unfortunately, no specific therapeutic options are currently available. Only supportive measures can be applied at the moment.29


There is no specific antiviral treatment recommended for COVID-19, and no vaccine is currently available. There are several worldwide efforts at developing vaccines against SARS-CoV-2. However, it is already clear that these vaccination strategies will not be available until 2021 at the earliest and will thus not be of any help for immediate countermeasures. Thus, antiviral drugs are urgently needed.

New drug licensing as well as repurposing the indications for drugs that are already in clinical use for other diseases would be the most promising options in the short term. Several of these drug candidates have been proposed and tested, including the human immunodeficiency virus (HIV) drug lopinavir/ritonavir, the antimalarial drugs chloroquine and hydroxychloroquine, and remdesivir, an inhibitor of RNA polymerase with in vitro activity against multiple RNA viruses, including Ebola. However, the results of many of these initial trials suffer from small sample sizes and/or nonrigorous study design.

When lopinavir/ritonavir was tested in a rigorous randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, no benefit was observed beyond standard care.30 While a recent trial using hydroxychloroquine was more promising and showed that treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients,31 this study included only a small number of individuals and therefore considered to have very limited validity. Preclinical studies suggested that remdesivir (GS5734) could be effective for both prophylaxis and therapy of HCoVs infections.32 This drug was positively tested in a rhesus macaque model of MERS-CoV infection33 and has been reported to treat the first case in the United States of COVID-19 successfully.34 Accordingly, 2 large clinical trials, NCT04252664 for mild/moderate COVID-19 and NCT04257656 for severe COVID-19, were initiated in China, with an estimated end date in early April 2020.

Similarly, the current lack of valid, rigorous clinical studies has prompted many clinical trials around the world. As one example, Europe has begun large joint clinical studies of experimental drugs to treat COVID-19. The trials will include 3200 patients in the Netherlands, Belgium, Luxembourg, the United Kingdom, France, and Spain, to test the clinical efficacy of the antiviral drugs remdesivir, lopinavir/ritonavir (+/− interferon), and hydroxychloroquine (NCT04315948).


Name: Stephan Ludwig, PhD.

Contribution: This author helped write and revise the manuscript.

Name: Alexander Zarbock, MD.

Contribution: This author helped write and revise the manuscript.

This manuscript was handled by: Thomas R. Vetter, MD, MPH.


1. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 February 24 [Epub ahead of print].
2. International Committee on Taxonomy of Viruses (ICTV). Virus Taxonomy: 2018b Release. 2019. Available at: Accessed April 8, 2020.
3. Drosten C, Preiser W, Günther S, Schmitz H, Doerr HW. Severe acute respiratory syndrome: identification of the etiological agent. Trends Mol Med. 2003;9:325–327.
4. Woo PC, Lau SK, Huang Y, Yuen KY. Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med (Maywood). 2009;234:1117–1127.
5. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23.
6. Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res. 2019;105:93–116.
7. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–14621.
8. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet. 2008;9:267–276.
9. Lai MM. RNA recombination in animal and plant viruses. Microbiol Rev. 1992;56:61–79.
10. Beaudette F, Hudson C. Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc. 1937;90:51–58.
11. Saif LJ. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev Sci Tech. 2004;23:643–660.
12. Drexler JF, Corman VM, Drosten C. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 2014;101:45–56.
13. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med. 1966;121:190–193.
14. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A. 1967;57:933–940.
15. Corman VM, Lienau J, Witzenrath M. Coronaviruses as the cause of respiratory infections. Internist (Berl). 2019;60:1136–1145.
16. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
17. Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163–188.
18. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
19. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12:222.
20. Zhu N, Zhang D, Wang W, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
21. Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020 March 3 [Epub ahead of print].
22. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
23. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
24. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386–389.
25. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069.
26. Poutanen SM, Low DE, Henry B, et al.; National Microbiology Laboratory, Canada; Canadian Severe Acute Respiratory Syndrome Study Team. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
27. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
28. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 February 28 [Epub ahead of print].
29. Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. JAMA. 2020 March 26 [Epub ahead of print].
30. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 March 18 [Epub ahead of print].
31. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949.
32. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020 February 24 [Epub ahead of print].
33. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117:6771–6776.
34. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936.
Copyright © 2020 International Anesthesia Research Society